| Kampman, Kyle |
VA-BRAVE, NCT04375033: A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder |
|
|
| Recruiting | 4 | 952 | US | Sublingual buprenorphine with naloxone, Injectable subcutaneous buprenorphine | VA Office of Research and Development | Opioid Use Disorder | 09/28 | 05/29 | | |
| Recruiting | 4 | 60 | US | XR-NTX 380 mg, intramuscular injection, Vivitrol naltrexone for extended-release injectable suspension, Medical Management, Placebo intramuscular injection, Inactive placebo | University of Pennsylvania, Alkermes, Inc. | Alcohol Use Disorder, Alcoholism | 11/25 | 11/26 | | |
NCT05551754: Acute Effects of Ketone Supplement on Responses to Alcohol Challenge in Healthy Volunteers |
|
|
| Active, not recruiting | 2/3 | 10 | US | Ketone Supplement, ketone supplement, D-hydroxybutyric acid and 1,3 butanediol, Alcohol Beverage | University of Pennsylvania | Alcohol Drinking | 07/25 | 07/26 | | |
| Recruiting | 2/3 | 20 | US | Ketone Supplement, D-Beta-hydroxybutyric acid and R-1,3 butanediol, Control Diet, ~ 50% kcal carbohydrates diet, Ketogenic diet, ~5-10% kcal carbohydrates diet, Ethanol, Alcohol | University of Pennsylvania | Ketoses, Metabolic, Ketogenic Dieting, Alcohol Intoxication, Magnetic Resonance Imaging, Alcohol Drinking | 12/25 | 12/26 | | |
PGB-LOF, NCT04218240: Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal |
|
|
| Completed | 2 | 90 | US | Pregabalin 200 MG capsules, lyrica, Placebo oral tablet, Lofexidine 0.18Mg Tab, lucemyra | University of Pennsylvania | Opioid Withdrawal | 03/23 | 03/23 | | |
NCT05562349: Clavulanic Acid for the Treatment of Cocaine Use Disorder |
|
|
| Active, not recruiting | 2 | 65 | US | Clavulanic Acid Only Product, Potassium clavulanate, Placebo, microcrystalline cellulose | Temple University, University of Pennsylvania, Medical University of South Carolina, Research Foundation for Mental Hygiene, Inc. | Cocaine Dependence | 07/24 | 07/24 | | |
NCT05063201: Cariprazine for Comorbid Cocaine and Opioid Use Disorder |
|
|
| Recruiting | 2 | 48 | US | Cariprazine 1.5 MG, Placebo | Kyle Kampman, National Institute on Drug Abuse (NIDA) | Opioid-use Disorder, Cocaine Use Disorder | 04/25 | 10/25 | | |
ROLDI, NCT06379984: Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD with Fentanyl Use |
|
|
| Recruiting | 2 | 60 | US | Buprenorphine | University of Pennsylvania, National Institute on Drug Abuse (NIDA) | Opioid Use Disorder | 12/25 | 12/25 | | |
UH3, NCT05995535: Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal |
|
|
| Recruiting | 2 | 150 | US | LFX/PGB, Lucemyra, lyrica, LFX/PLA-PGB, placebo pregabalin | University of Pennsylvania | Opiate Withdrawal Syndrome, Opioid Use | 08/26 | 08/26 | | |
| Recruiting | 2 | 50 | US | Ibudilast, MN-166, previously known as AV411 and the formulation is 10-mg delayed-release Pinatos® capsules, Medical management, Placebo, Inactive substance | University of Pennsylvania | Alcohol Use Disorder (AUD), Alcoholism | 12/27 | 12/28 | | |
